Table 3.
Subgroup analysis of risk ratios for immune-related adverse events (irAEs) comparing ICI therapy with chemotherapy.
| Subgroup analysis a | Grade 3–5 irAEs | All-grade irAEs | ||||
|---|---|---|---|---|---|---|
| I 2 (P) | RR (95% CI) | Z and P | I 2 (P) | RR (95% CI) | Z and P | |
| Overall | 95.7% (0.000) | 3.151 (2.175, 4.563) | Z = 6.07, P = 0.000 | 80.1% (0.000) | 3.851 (2.767, 5.359) | Z = 8.00, P = 0.000 |
| Subgroup | ||||||
| Treatment lines | ||||||
| Second-line | 51.6% (0.151) | 3.387 (0.690, 16.635) | Z = 1.50, P = 0.133 | 89.8% (0.000) | 4.036 (1.833, 8.888) | Z = 3.46, P = 0.001 |
| First-line | 37.6% (0.201) | 3.011 (1.880, 4.823) | Z = 4.59, P = 0.000 | 87.0% (0.000) | 3.653 (2.430, 5.493) | Z = 6.23, P = 0.000 |
| Third-line | 0.0% (0.823) | 9.716 (1.849, 51.060) | Z = 2.69, P = 0.007 | 60.8% (0.078) | 7.513 (1.096, 51.516) | Z = 2.05, P = 0.040 |
| ICI drugs | ||||||
| PD-1 | 0.0% (0.504) | 2.484 (1.620, 3.807) | Z = 4.17, P = 0.000 | 85.3% (0.000) | 3.464 (2.280, 5.262) | Z = 5.82, P = 0.000 |
| CTLA-4 | 9.4% (0.293) | 4.729 (2.071, 10.798) | Z = 3.69, P = 0.000 | 19.0% (0.267) | 5.562 (2.176, 14.215) | Z = 3.58, P = 0.000 |
| PD-L1 | – | 8.659 (0.470, 159.675) | Z = 1.45, P = 0.147 | – | 24.054 (1.435, 403.229) | Z = 2.21, P = 0.027 |
| Treatment mode | ||||||
| ICIs alone | 0.0% (0.943) | 9.690 (2.670, 35.166) | Z = 3.45, P = 0.001 | 76.9% (0.002) | 5.099 (2.396, 10.850) | Z = 4.23, P = 0.000 |
| ICIs + ChT | 23.4% (0.270) | 2.839 (1.892, 4.261) | Z = 5.04, P = 0.000 | 84.5% (0.000) | 3.357 (2.320, 4.858) | Z = 6.42, P = 0.000 |
| Sample size | ||||||
| <500 | 0.0% (0.943) | 9.690 (2.670, 35.166) | Z = 3.45, P = 0.001 | 68.8% (0.022) | 6.573 (2.383, 18.128) | Z = 3.64, P = 0.000 |
| ≥500 | 23.4% (0.270) | 2.839 (1.892, 4.261) | Z = 5.04, P = 0.000 | 80.0% (0.000) | 3.329 (2.432, 4.559) | Z = 7.50, P = 0.000 |
a
Subgroup analyses were conducted based on the pairwise comparisons of all individual trials.